FDA Releases Additional Information ahead of Listeria Prevention Public Meeting

August 3, 2026

The FDA is sharing additional information ahead of the public meeting on Listeria monocytogenes prevention planned for August 18–19, 2026.

During the upcoming public meeting the FDA hopes to foster discussions around a number of topics including:

Advances in the Understanding and Control of L. monocytogenes
Best Practices in L. monocytogenes prevention
L. monocytogenes Dose-Response Modeling: Applications and Advancements
Using Food Safety Management Systems for Controlling L. monocytogenes in Retail Environments
Preventing Listeriosis in an Era of Changing Demographics and Dietary Patterns

Today, the agency released an agenda for the public meeting which outlines several sessions focused on these topics and a document outlining key questions the agency hopes will inform discussions both during and beyond the public meeting. Additionally, FDA has opened a docket where interested stakeholders can submit comments related to these topics, the key questions, or other helpful information related to Listeria prevention. The docket will be open for 90 days.

As a reminder, registration is currently open for the public meeting. More information can be found on the meeting webpage.

For More Information

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.

R.G. Client

I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.

Mike H. Client

Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.

Dr. Sastry Client

I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.

Claire P. Client